Clint, a former federal prosecutor, is a member of the firm’s nationally ranked Government Investigations and White Collar Litigation Department. An experienced litigator, Clint represents companies and individuals in high-stakes criminal and white collar litigation, government investigations, and regulatory enforcement proceedings. Clint also assists clients by conducting internal investigations, developing corporate compliance programs, undertaking transactional diligence, and advising on regulatory and compliance issues impacting health care and life sciences companies, particularly with respect to the Federal Food, Drug and Cosmetic Act (FDCA). He joins McGuireWoods after serving nearly four years as an assistant director of the United States Department of Justice (DOJ) Consumer Protection Branch.
In his role at the DOJ, Clint was instrumental in personally handling and overseeing complex, high-profile investigations and prosecutions involving, among other areas, pharmaceuticals and medical devices, research misconduct and clinical trial fraud, drug diversion and supply chain integrity, health care fraud, financial fraud, pharmacy compounding, elder fraud and nursing home fraud, and food and dietary supplements. Clint developed expertise in managing large-scale corporate investigations in several industries—including in the health care, life sciences, and consumer products and services sectors—and worked closely with agency partners to include the FBI, DEA, FDA, FTC, U.S. Postal Inspection Service, HHS Office of Inspector General, and state attorneys general. His experience includes matters involving the FDCA, the False Claims Act, the Anti-Kickback statute, the Controlled Substances Act, the Consumer Product Safety Act, the Federal Trade Commission Act, and various fraud, customs, and money laundering statutes.
Before his tenure at the DOJ, Clint served in various capacities with the FDA’s Office of the Chief Counsel, where he developed a keen insight into the FDA’s inner workings and regulatory processes. While with the FDA, Clint supported the agency’s Health Care Fraud and Abuse Control (HCFAC) program, worked closely with the Center for Drug Evaluation and Research, the Center for Devices and Radiological Health, and the FDA’s Office of Criminal Investigations, and advised the agency in connection with research misconduct investigations overseen by the HHS Office of Research Integrity. Clint also served as a Special Assistant U.S. Attorney in multiple jurisdictions, litigating cases at both the trial and appellate levels.
Clint’s unique background and experience enable him to provide insightful and practical advice to clients facing regulatory challenges. His proactive approach helps clients address potential issues before they escalate, ensuring compliance and minimizing risk. In situations where the government pursues enforcement action, Clint leverages his extensive prosecutorial experience to aggressively defend his clients’ rights in litigation.
-
University of Pennsylvania Carey Law SchoolJD
magna cum laude, Order of the Coif
2000 - University of California, BerkeleyBA1996
- Presenter, "What the DOJ and FDA are Looking for in Compliance Programs," Compliance Conversations by Healthicity, January 30, 2025
- Moderator, "FDA and DOJ Clinical Trials Oversight – The Impact of Industry Modernization and Best Practices," Food and Drug Law Institute (FDLI), Enforcement, Litigation, and Compliance Conference, December 10, 2024
- Presenter, "Research Fraud and Misconduct," Health Care Compliance Association (HCCA), Healthcare Enforcement Compliance Conference, November 20, 2024
- Panelist, "Life Sciences Regulatory Essentials: What Investors Should Know," 17th Annual Healthcare Finance & Growth Conference, September 25 - 26, 2024
- Presenter, "Enforcement Issues in Drug and Device Research," Health Care Compliance Association (HCCA), Research Compliance Conference, 2023
- Presenter, "Enforcement in Research," HCCA, Healthcare Enforcement Compliance Conference, 2023
- Presenter, "Clinical Trials: Deconstructing Challenges and Providing Practical Insights," Food and Drug Law Institute, 2022
- Hon. Alfred T. Goodwin, U.S. Court of Appeals for the Ninth Circuit, 2001-2002
- District of Columbia
- Author, Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies, McGuireWoods Legal Alert, January 29, 2025
- Author, Dairy Industry Alerted to New USDA Order Requiring National Raw Milk Testing, McGuireWoods Legal Alert, December 10, 2024
- Author, Recent FDA Guidance Signals Future Growth for Decentralized Clinical Trials, McGuireWoods Legal Alert, October 24, 2024
- Author, Key Takeaways From the 2024 Healthcare Finance and Growth Conference, McGuireWoods Legal Alert, October 15, 2024